Cargando…

Disease-modifying effects of ranibizumab for central retinal vein occlusion

PURPOSE: To identify anatomic endpoints altered by intravitreal ranibizumab in central retinal vein occlusion (CRVO) to determine any potential underlying disease modification that occurs with anti-vascular endothelial growth factor (anti-VEGF) therapy beyond best-corrected visual acuity and central...

Descripción completa

Detalles Bibliográficos
Autores principales: Huang, Jason M., Khurana, Rahul N., Ghanekar, Avanti, Wang, Pin-wen, Day, Bann-Mo, Blodi, Barbara A., Domalpally, Amitha, Quezada-Ruiz, Carlos, Ip, Michael S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8850212/
https://www.ncbi.nlm.nih.gov/pubmed/34613454
http://dx.doi.org/10.1007/s00417-021-05224-x
_version_ 1784652544464650240
author Huang, Jason M.
Khurana, Rahul N.
Ghanekar, Avanti
Wang, Pin-wen
Day, Bann-Mo
Blodi, Barbara A.
Domalpally, Amitha
Quezada-Ruiz, Carlos
Ip, Michael S.
author_facet Huang, Jason M.
Khurana, Rahul N.
Ghanekar, Avanti
Wang, Pin-wen
Day, Bann-Mo
Blodi, Barbara A.
Domalpally, Amitha
Quezada-Ruiz, Carlos
Ip, Michael S.
author_sort Huang, Jason M.
collection PubMed
description PURPOSE: To identify anatomic endpoints altered by intravitreal ranibizumab in central retinal vein occlusion (CRVO) to determine any potential underlying disease modification that occurs with anti-vascular endothelial growth factor (anti-VEGF) therapy beyond best-corrected visual acuity and central optical coherence tomography outcomes. METHODS: A post hoc analysis of a double-masked, multicenter, randomized clinical trial was performed. A total of 392 patients with macular edema after CRVO were randomized 1:1:1 to receive monthly intraocular injections of 0.3 or 0.5 mg of ranibizumab or sham injections. Central reading center-read data were reviewed to explore potential anatomic endpoints altered by therapy. RESULTS: At 6 months, there was a reduction in the ranibizumab groups compared with sham groups with respect to total area of retinal hemorrhage (median change from baseline in disc areas: − 1.17 [sham], − 2.37 [ranibizumab 0.3 mg], − 1.64 [ranibizumab 0.5 mg]), development of disc neovascularization (prevalence: 3% [sham], 0% [ranibizumab 0.3 mg], 0% [ranibizumab 0.5 mg]), and presence of papillary swelling (prevalence: 22.9% [sham], 8.0% [ranibizumab 0.3 mg], 8.3% [ranibizumab 0.5 mg], p < 0.01). There was no difference between groups in collateral vessel formation. Analysis of vitreous and preretinal hemorrhage could not be performed due to low frequency of events in both treated and sham groups. CONCLUSIONS: Ranibizumab for CRVO resulted in beneficial disease-modifying effects through a reduction in retinal hemorrhage, neovascularization, and papillary swelling. These findings may form the basis for future work in the development of a treatment response or severity scale for eyes with CRVO.
format Online
Article
Text
id pubmed-8850212
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Springer Berlin Heidelberg
record_format MEDLINE/PubMed
spelling pubmed-88502122022-02-23 Disease-modifying effects of ranibizumab for central retinal vein occlusion Huang, Jason M. Khurana, Rahul N. Ghanekar, Avanti Wang, Pin-wen Day, Bann-Mo Blodi, Barbara A. Domalpally, Amitha Quezada-Ruiz, Carlos Ip, Michael S. Graefes Arch Clin Exp Ophthalmol Retinal Disorders PURPOSE: To identify anatomic endpoints altered by intravitreal ranibizumab in central retinal vein occlusion (CRVO) to determine any potential underlying disease modification that occurs with anti-vascular endothelial growth factor (anti-VEGF) therapy beyond best-corrected visual acuity and central optical coherence tomography outcomes. METHODS: A post hoc analysis of a double-masked, multicenter, randomized clinical trial was performed. A total of 392 patients with macular edema after CRVO were randomized 1:1:1 to receive monthly intraocular injections of 0.3 or 0.5 mg of ranibizumab or sham injections. Central reading center-read data were reviewed to explore potential anatomic endpoints altered by therapy. RESULTS: At 6 months, there was a reduction in the ranibizumab groups compared with sham groups with respect to total area of retinal hemorrhage (median change from baseline in disc areas: − 1.17 [sham], − 2.37 [ranibizumab 0.3 mg], − 1.64 [ranibizumab 0.5 mg]), development of disc neovascularization (prevalence: 3% [sham], 0% [ranibizumab 0.3 mg], 0% [ranibizumab 0.5 mg]), and presence of papillary swelling (prevalence: 22.9% [sham], 8.0% [ranibizumab 0.3 mg], 8.3% [ranibizumab 0.5 mg], p < 0.01). There was no difference between groups in collateral vessel formation. Analysis of vitreous and preretinal hemorrhage could not be performed due to low frequency of events in both treated and sham groups. CONCLUSIONS: Ranibizumab for CRVO resulted in beneficial disease-modifying effects through a reduction in retinal hemorrhage, neovascularization, and papillary swelling. These findings may form the basis for future work in the development of a treatment response or severity scale for eyes with CRVO. Springer Berlin Heidelberg 2021-10-06 2022 /pmc/articles/PMC8850212/ /pubmed/34613454 http://dx.doi.org/10.1007/s00417-021-05224-x Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Retinal Disorders
Huang, Jason M.
Khurana, Rahul N.
Ghanekar, Avanti
Wang, Pin-wen
Day, Bann-Mo
Blodi, Barbara A.
Domalpally, Amitha
Quezada-Ruiz, Carlos
Ip, Michael S.
Disease-modifying effects of ranibizumab for central retinal vein occlusion
title Disease-modifying effects of ranibizumab for central retinal vein occlusion
title_full Disease-modifying effects of ranibizumab for central retinal vein occlusion
title_fullStr Disease-modifying effects of ranibizumab for central retinal vein occlusion
title_full_unstemmed Disease-modifying effects of ranibizumab for central retinal vein occlusion
title_short Disease-modifying effects of ranibizumab for central retinal vein occlusion
title_sort disease-modifying effects of ranibizumab for central retinal vein occlusion
topic Retinal Disorders
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8850212/
https://www.ncbi.nlm.nih.gov/pubmed/34613454
http://dx.doi.org/10.1007/s00417-021-05224-x
work_keys_str_mv AT huangjasonm diseasemodifyingeffectsofranibizumabforcentralretinalveinocclusion
AT khuranarahuln diseasemodifyingeffectsofranibizumabforcentralretinalveinocclusion
AT ghanekaravanti diseasemodifyingeffectsofranibizumabforcentralretinalveinocclusion
AT wangpinwen diseasemodifyingeffectsofranibizumabforcentralretinalveinocclusion
AT daybannmo diseasemodifyingeffectsofranibizumabforcentralretinalveinocclusion
AT blodibarbaraa diseasemodifyingeffectsofranibizumabforcentralretinalveinocclusion
AT domalpallyamitha diseasemodifyingeffectsofranibizumabforcentralretinalveinocclusion
AT quezadaruizcarlos diseasemodifyingeffectsofranibizumabforcentralretinalveinocclusion
AT ipmichaels diseasemodifyingeffectsofranibizumabforcentralretinalveinocclusion